Skip to main content
Fig. 1 | Journal of Experimental & Clinical Cancer Research

Fig. 1

From: Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples

Fig. 1

Liquid biopsy, non invasive and low-risk procedure, allows to monitor the changing and evolving landscape of cancer in real-time during the course of disease. In blood vessels, circulating tumor DNA (ctDNA), circulating tumor RNA (ctRNA), non-coding RNAs, circulating tumor cells (CTCs), and circulating leukocytes represent promising biomarkers to assess tumor heterogeneity and patients’ treatment response

Back to article page